Recent Updates — APVO
Aptevo Therapeutics announced that ten patients (21%) with newly diagnosed acute myeloid leukemia treated with mipletamig in combination with venetoclax and azacitidine have advanced to allogeneic stem cell transplant. This rate compares favorably with the 0.7% historical transplant rate observed with standard-of-care venetoclax and azacitidine alone, adding clinical evidence supporting the drug's potential to improve outcomes in patients initially deemed unfit for intensive chemotherapy. The company expects its RAINIER dose optimization trial to conclude by year-end 2026, with an FDA interaction and initiation of a Phase 2 clinical trial anticipated in the first half of 2027. Aptevo Therapeutics is a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics for cancer.
Aptevo Therapeutics Inc. entered into Amendment No. 6 to its Rights Agreement, extending the Final Expiration Date of its shareholder rights plan (poison pill) from October 23, 2026, to October 23, 2027. The amendment also modifies the Purchase Price for acquiring Preferred Shares to $14.56 per one-thousandth of a share. This adjustment maintains the company's defense against unsolicited acquisition attempts while updating the financial terms associated with the rights plan. Aptevo Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases.
Aptevo Therapeutics announced it will showcase its multispecific platform, specifically a CD40-directed portfolio designed to coordinate innate and adaptive immune activity within the tumor microenvironment, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentation is scheduled for November 4–8, 2026, in Phoenix, Arizona. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel multispecific immunotherapies for the treatment of cancer.
Aptevo Therapeutics Inc. announced a 93% clinical benefit rate for its mipletamig triplet therapy in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations. Among 14 evaluable patients, 13 experienced clinical benefit, including an 11-patient complete remission or complete remission with incomplete hematologic recovery (CR/CRi) rate of 79%. These results nearly double the published venetoclax plus azacitidine outcomes for this difficult-to-treat population. The RAINIER study is expected to complete dose optimization by year-end, with regulatory interaction planned for the first half of 2027. Aptevo Therapeutics Inc. operates in the biotechnology industry, developing novel multispecific immuno-oncology therapeutics.